These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 21750497)

  • 1. The evolution of antiplatelet therapy in cardiovascular disease.
    Yousuf O; Bhatt DL
    Nat Rev Cardiol; 2011 Jul; 8(10):547-59. PubMed ID: 21750497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical use of clopidogrel.
    Sarafoff N; Byrne RA; Sibbing D
    Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The state of periprocedural antiplatelet therapy after recent trials.
    Desai NR; Bhatt DL
    JACC Cardiovasc Interv; 2010 Jun; 3(6):571-83. PubMed ID: 20630450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
    Tan GM; Lam YY; Yan BP
    Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Status of Antiplatelet Therapy in Acute Coronary Syndrome.
    Dash D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):40-9. PubMed ID: 26245659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet drugs: which targets for which treatments?
    Gachet C
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S313-22. PubMed ID: 26149041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
    Abergel E; Nikolsky E
    Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New anti-platelet agents: the end of resistance?
    Kastrati A
    Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antiplatelet therapies in development.
    Price MJ
    Am J Health Syst Pharm; 2008 Jul; 65(13 Suppl 5):S11-5; quiz S16-8. PubMed ID: 18574020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving role of platelet function testing in coronary artery interventions.
    Sharma RK; Voelker DJ; Sharma R; Reddy HK; Dod H; Marsh JD
    Vasc Health Risk Manag; 2012; 8():65-75. PubMed ID: 22371653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why we need intravenous antiplatelet agents.
    Tyler JM; Burris RJ; Seto AH
    Future Cardiol; 2016 Sep; 12(5):553-61. PubMed ID: 27255111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current options in oral antiplatelet strategies during percutaneous coronary interventions.
    Tantry US; Gurbel PA
    Rev Cardiovasc Med; 2011; 12 Suppl 1():S4-13. PubMed ID: 22080986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
    Laine M; Camoin-Jau L; Bessereau J; Sébastien A; Paganelli F; Bonello L
    Curr Pharm Des; 2012; 18(33):5392-401. PubMed ID: 22724420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and clinical use of prasugrel and ticagrelor.
    Ahmad S; Storey RF
    Curr Pharm Des; 2012; 18(33):5240-60. PubMed ID: 22724412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
    Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
    Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.